^
    Back
    Association details:
    Biomarker:miR-34a expression
    Cancer:Triple Negative Breast Cancer
    Drug:Xpovio (selinexor) (XPO1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Pharmaceuticals (Basel)
    Title:

    miR-34a-Mediated Survivin Inhibition Improves the Antitumor Activity of Selinexor in Triple-Negative Breast Cancer

    Published date:
    05/29/2021
    Excerpt:
    ...miR-34a expression markedly enhanced selinexor antitumor activity in the less sensitive TNBC xenograft model.
    DOI:
    10.3390/ph14060523